Dyslipidemia treatment is of major importance in reducing the risk of atherosclerotic cardiovascular disease (ASCVD), which is still the most common cause of death worldwide. During the last decade, a novel lipid-lowering drug category has emerged, i.e., proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Apart from the two available anti-PCSK9 monoclonal antibodies (alirocumab and evolocumab), other nucleic acid-based therapies that inhibit or "silence" the expression of PCSK9 are being developed. Among them, inclisiran is the first-in-class small interfering RNA (siRNA) against PCSK9 that has been approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of hypercholesterolemia. Importantly, inclisiran therapy may improve low-density lipoprotein cholesterol (LDL-C) target achievement by offering a prolonged and significant LDL-C-lowering effect with the administration of only two doses per year. The present narrative review discusses the ORION/VICTORION clinical trial program that has been designed to investigate the impact of inclisiran on atherogenic lipoproteins and major adverse cardiac events in different patient populations. The results of the completed clinical trials are presented, focusing on the effects of inclisiran on LDL-C and lipoprotein (a) (Lp(a)) levels as well as on other lipid parameters such as apolipoprotein B and non-high-density lipoprotein cholesterol (non-HDL-C). Ongoing clinical trials with inclisiran are also discussed.

3rd Department of Medicine Department of Endocrinology and Metabolism of the 1st Faculty of Medicine Charles University and General University Hospital 121 08 Prague Czech Republic

Center for Endocrinology Diabetes and Preventive Medicine University of Cologne Faculty of Medicine and University Hospital Cologne Kerpener Str 62 50937 Cologne Germany

Department of Nutritional Sciences and Dietetics International Hellenic University 574 00 Thessaloniki Greece

Department of Preventive Cardiology and Lipidology Medical University of Lodz and Polish Mother's Memorial Hospital Research Institute 93 338 Lodz Poland

School of Medicine European University Cyprus Nicosia 2404 Cyprus

See more in PubMed

GBD 2017 Causes of Death Collaborators Global, Regional, and National Age-Sex-Specific Mortality for 282 Causes of Death in 195 Countries and Territories, 1980–2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736–1788. doi: 10.1016/S0140-6736(18)32203-7. PubMed DOI PMC

Grundy S.M., Stone N.J., Bailey A.L., Beam C., Birtcher K.K., Blumenthal R.S., Braun L.T., de Ferranti S., Faiella-Tommasino J., Forman D.E., et al. 2018 HA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082–e1143. PubMed PMC

Katsiki N., Giannoukas A.D., Athyros V.G., Mikhailidis D.P. Lipid-lowering treatment in peripheral artery disease. Curr. Opin. Pharmacol. 2018;39:19–26. doi: 10.1016/j.coph.2018.01.003. PubMed DOI

Katsiki N., Athyros V.G., Mikhailidis D.P., Mantzoros C. Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial. Metabolism. 2017;74:43–46. doi: 10.1016/j.metabol.2017.04.007. PubMed DOI

Liu C., Chen J., Chen H., Zhang T., He D., Luo Q., Chi J., Hong Z., Liao Y., Zhang S., et al. PCSK9 Inhibition: From Current Advances to Evolving Future. Cells. 2022;11:2972. doi: 10.3390/cells11192972. PubMed DOI PMC

Authors/Task Force Members. ESC Committee for Practice Guidelines (CPG) ESC National Cardiac Societies 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140–205. doi: 10.1016/j.atherosclerosis.2019.08.014. PubMed DOI

Visseren F.L.J., Mach F., Smulders Y.M., Carballo D., Koskinas K.C., Bäck M., Benetos A., Biffi A., Boavida J.M., Capodanno D., et al. ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC) Rev. Esp. Cardiol. 2022;75:429. PubMed

Toth P.P., Jones S.R., Monsalvo M.L., Elliott-Davey M., López J.A.G., Banach M. Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies. J. Am. Heart Assoc. 2020;9:e014129. doi: 10.1161/JAHA.119.014129. PubMed DOI PMC

Gouni-Berthold I., Schwarz J., Berthold H.K. PCSK9 Monoclonal Antibodies: New Developments and Their Relevance in a Nucleic Acid-Based Therapy Era. Curr. Atheroscler. Rep. 2022;24:779–790. doi: 10.1007/s11883-022-01053-3. PubMed DOI PMC

Lyall D.M., Ward J., Banach M., Smith G.D., Gill J.G., Pell J.P., Holmes M.V., Sattar N. PCSK9 genetic variants and cognitive abilities: A large-scale Mendelian randomization study. Arch. Med. Sci. 2021;17:241–244. doi: 10.5114/aoms/127226. PubMed DOI PMC

Ruscica M., Greco M.F., Ferri N., Corsini A. Lipoprotein(a) and PCSK9 inhibition: Clinical evidence. Eur. Heart J. Suppl. 2020;22:L53–L56. doi: 10.1093/eurheartj/suaa135. PubMed DOI PMC

Sahebkar A., Momtazi-Borojeni A.A., Banach M. PCSK9 vaccine: So near, yet so far! Eur. Heart J. 2021;42:4007–4010. doi: 10.1093/eurheartj/ehab299. PubMed DOI

Kulkarni J.A., Witzigmann D., Thomson S.B., Chen S., Leavitt B.R., Cullis P.R., van der Meel R. The current landscape of nucleic acid therapeutics. Nat. Nanotechnol. 2021;16:630–643. doi: 10.1038/s41565-021-00898-0. PubMed DOI

[(accessed on 24 March 2023)]; Available online: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-add-therapy-lower-cholesterol-among-certain-high-risk-adults.

[(accessed on 24 March 2023)]. Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/leqvio.

Kosmas C.E., Muñoz Estrella A., Skavdis A., Peña Genao E., Martinez I., Guzman E. Inclisiran for the Treatment of Cardiovascular Disease: A Short Review on the Emerging Data and Therapeutic Potential. Ther. Clin. Risk Manag. 2020;16:1031–1037. doi: 10.2147/TCRM.S230592. PubMed DOI PMC

Arnold N., Koenig W. PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection. Curr. Cardiol. Rep. 2022;24:1657–1667. doi: 10.1007/s11886-022-01782-6. PubMed DOI PMC

Ray K.K., Stoekenbroek R.M., Kallend D., Nishikido T., Leiter L.A., Landmesser U., Wright R.S., Wijngaard P.L.J., Kastelein J.J.P. Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial. JAMA Cardiol. 2019;4:1067–1075. doi: 10.1001/jamacardio.2019.3502. PubMed DOI PMC

Hovingh G.K., Lepor N.E., Kallend D., Stoekenbroek R.M., Wijngaard P.L.J., Raal F.J. Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study. Circulation. 2020;141:1829–1831. doi: 10.1161/CIRCULATIONAHA.119.044431. PubMed DOI

Ray K.K., Troquay R.P.T., Visseren F.L.J., Leiter L.A., Scott Wright R., Vikarunnessa S., Talloczy Z., Zang X., Maheux P., Lesogor A., et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): Results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol. 2023;11:109–119. doi: 10.1016/S2213-8587(22)00353-9. PubMed DOI

Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People with Cardiovascular Disease (ORION-4) [(accessed on 24 March 2023)]; Available online: https://clinicaltrials.gov/ct2/show/NCT03705234.

[(accessed on 24 March 2023)]; Available online: https://www.clinicaltrials.gov/ct2/show/results/NCT03851705?cond=NCT03851705&draw=2&rank=1.

Kallend D., Stoekenbroek R., He Y., Smith P.F., Wijngaard P. Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment. J. Clin. Lipidol. 2022;16:208–219. doi: 10.1016/j.jacl.2022.01.001. PubMed DOI

Wrigh R.S., Collins M.G., Stoekenbroek R.M., Robson R., Wijngaard P.L.J., Landmesser U., Leiter L.A., Kastelein J.J.P., Ray K.K., Kallend D. Effects of Renal Impairment on the Pharmacokinetics, Efficacy, and Safety of Inclisiran: An Analysis of the ORION-7 and ORION-1 Studies. Mayo Clin. Proc. 2020;95:77–89. doi: 10.1016/j.mayocp.2019.08.021. PubMed DOI

Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects with High CV Risk and Elevated LDL-C (ORION-8). ClinicalTrials.gov Identifier: NCT03814187. [(accessed on 24 March 2023)]; Available online: https://clinicaltrials.gov/ct2/show/NCT03814187.

Raal F.J., Kallend D., Ray K.K., Turner T., Koenig W., Wright R.S., Wijngaard P.L.J., Curcio D., Jaros M.J., Leiter L.A., et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N. Engl. J. Med. 2020;382:1520–1530. doi: 10.1056/NEJMoa1913805. PubMed DOI

Ray K.K., Wright R.S., Kallend D., Koenig W., Leiter L.A., Raal F.J., Bisch J.A., Richardson T., Jaros M., Wijngaard P.L.J., et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N. Engl. J. Med. 2020;382:1507–1519. doi: 10.1056/NEJMoa1912387. PubMed DOI

Scicchitano P., Milo M., Mallamaci R., De Palo M., Caldarola P., Massari F., Gabrielli D., Colivicchi F., Ciccone M.M. Inclisiran in lipid management: A Literature overview and future perspectives. Biomed. Pharmacother. 2021;143:112227. doi: 10.1016/j.biopha.2021.112227. PubMed DOI

[(accessed on 24 March 2023)]; Available online: https://clinicaltrials.gov/ct2/show/NCT04659863.

[(accessed on 24 March 2023)]; Available online: https://clinicaltrials.gov/ct2/show/NCT04774003.

[(accessed on 24 March 2023)]; Available online: https://clinicaltrials.gov/ct2/show/NCT04652726.

[(accessed on 24 March 2023)]; Available online: https://clinicaltrials.gov/ct2/show/NCT04765657.

[(accessed on 24 March 2023)]; Available online: https://clinicaltrials.gov/ct2/show/NCT04929249.

[(accessed on 24 March 2023)]; Available online: https://clinicaltrials.gov/ct2/show/NCT04873934.

[(accessed on 24 March 2023)]; Available online: https://clinicaltrials.gov/ct2/show/NCT05030428.

[(accessed on 24 March 2023)]; Available online: https://clinicaltrials.gov/ct2/history/NCT05399992.

[(accessed on 24 March 2023)]; Available online: https://clinicaltrials.gov/ct2/show/NCT05192941.

[(accessed on 24 March 2023)]; Available online: https://clinicaltrials.gov/ct2/show/NCT05362903.

[(accessed on 24 March 2023)]; Available online: https://clinicaltrials.gov/ct2/show/NCT05360446.

[(accessed on 24 March 2023)]; Available online: https://clinicaltrials.gov/ct2/show/NCT04807400.

Koenig W., Conde L.G., Landmesser U., Leiter L.A., Ray K.K., Schwartz G.G., Wright R.S., Han J., Raal F.J. Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials. Cardiovasc. Drugs Ther. 2022 doi: 10.1007/s10557-022-07413-0. epub ahead of print . PubMed DOI PMC

Ray K.K., Stoekenbroek R.M., Kallend D., Leiter L.A., Landmesser U., Wright R.S., Wijngaard P., Kastelein J.J.P. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1. Circulation. 2018;138:1304–1316. doi: 10.1161/CIRCULATIONAHA.118.034710. PubMed DOI

Leiter L.A., Teoh H., Kallend D., Wright R.S., Landmesser U., Wijngaard P.L.J., Kastelein J.J.P., Ray K.K. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial. Diabetes Care. 2019;42:173–176. doi: 10.2337/dc18-1491. PubMed DOI

Ray K.K., Kallend D., Leiter L.A., Raal F.J., Koenig W., Jaros M.J., Schwartz G.G., Landmesser U., Garcia Conde L., Wright R.S., et al. Effect of inclisiran on lipids in primary prevention: The ORION-11 trial. Eur. Heart J. 2022;43:5047–5057. doi: 10.1093/eurheartj/ehac615. PubMed DOI PMC

Fitzgerald K., White S., Borodovsky A., Bettencourt B.R., Strahs A., Clausen V., Wijngaard P., Horton J.D., Taubel J., Brooks A., et al. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. N. Engl. J. Med. 2017;376:41–51. doi: 10.1056/NEJMoa1609243. PubMed DOI PMC

Banach M., Kaźmierczak J., Mitkowski P., Wita K., Broncel M., Gąsior M., Gierlotka M., Gil R., Jankowski P., Niewada M., et al. Which patients at risk of cardiovascular disease might benefit the most from inclisiran? Polish experts’ opinion. The compromise between EBM and possibilities in healthcare. Arch. Med. Sci. 2022;18:569–576. doi: 10.5114/aoms/147435. PubMed DOI PMC

Dyrbuś K., Gąsior M., Penson P., Ray K.K., Banach M. Inclisiran-New hope in the management of lipid disorders? J. Clin. Lipidol. 2020;14:16–27. doi: 10.1016/j.jacl.2019.11.001. PubMed DOI

Ray K.K., Raal F.J., Kallend D.G., Jaros M.J., Koenig W., Leiter L.A., Landmesser U., Schwartz G.G., Lawrence D., Friedman A., et al. Inclisiran and cardiovascular events: A patient-level analysis of phase III trials. Eur. Heart J. 2023;44:129–138. doi: 10.1093/eurheartj/ehac594. PubMed DOI PMC

Lp(a)-Lowering Agents in Development: A New Era in Tackling the Burden of Cardiovascular Risk?

2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP)